The lead­ers in the race to de­vel­op a Covid-19 vac­cine say they could have piv­otal da­ta in Oc­to­ber — but Trump claims FDA is slow­ing re­cruit­ment

Late Fri­day night Mod­er­na tweet­ed that their Phase III study had come close to the halfway mark in re­cruit­ing the 30,000 or so sub­jects need­ed for the piv­otal test of their Covid-19 vac­cine mR­NA-1273.

So I thought it was a good time to catch up with CEO Stéphane Ban­cel on the tim­ing of the read­out, which is of in­tense in­ter­est around the world — and par­tic­u­lar­ly in Wash­ing­ton DC, where the top reg­u­la­tors and sci­en­tists in­volved re­peat­ed­ly in­sist they won’t tol­er­ate any po­lit­i­cal in­ter­fer­ence in push­ing a pre­ma­ture an­nounce­ment of a win ahead of the elec­tion No­vem­ber 3rd.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE